In this study, the diabetes mellitus incidence was 2.6 per 100 patient-years, gradually decreasing from a peak of 4.1 per 100 patient-years in year 2 of GH replacement therapy to 1.0 per 100 patient-years after > 8 years of treatment, irrespective of gender. Here, GH1 is linked to diabetes mellitus.